

November 18, 2020

Q2FY21 Result Update

Change in Estimates | Target | Reco

Change in Estimates

	Cu	rrent	Prev	Previous		
	FY22E	FY23E	FY22E	FY23E		
Rating	E	BUY	JY BUY			
Target Price	2	288	2	88		
Sales (Rs. m)	27,299	31,023	27,299	31,025		
% Chng.	-	-				
EBITDA (Rs. m)	3,139	3,568	3,139	3,568		
% Chng.	-	-				
EPS (Rs.)	27.4	31.0	27.4	31.0		
% Chng.	-	-				

Key Financials - Standalone

Y/e Mar	FY20	FY21E	FY22E	FY23E
Sales (Rs. m)	18,849	17,915	27,299	31,023
EBITDA (Rs. m)	1,530	1,612	3,139	3,568
Margin (%)	8.1	9.0	11.5	11.5
PAT (Rs. m)	644	783	1,837	2,074
EPS (Rs.)	9.6	11.7	27.4	31.0
Gr. (%)	(45.1)	21.5	134.6	12.9
DPS (Rs.)	0.2	0.2	0.5	0.6
Yield (%)	0.1	0.1	0.2	0.3
RoE (%)	8.4	9.3	18.9	17.8
RoCE (%)	14.3	13.9	25.6	24.6
EV/Sales (x)	0.8	0.8	0.5	0.4
EV/EBITDA (x)	9.4	9.0	4.4	3.8
PE (x)	24.6	20.3	8.6	7.7
P/BV (x)	2.0	1.8	1.5	1.3

Key Data	AHLU.BO AHLU IN
52-W High / Low	Rs.370 / Rs.136
Sensex / Nifty	44,180 / 12,938
Market Cap	Rs.16bn/ \$ 214m
Shares Outstanding	67m
3M Avg. Daily Value	Rs.51.32m

Shareholding Pattern (%)

Promoter's	58.00
Foreign	15.06
Domestic Institution	23.45
Public & Others	3.49
Promoter Pledge (Rs bn)	3.86

Stock Performance (%)

	1M	6M	12M
Absolute	6.4	37.8	(13.7)
Relative	(3.7)	(6.3)	(21.3)

Viral Shah

viralshah@plindia.com | 91-22-66322250

Shivang Joshi

shivangjoshi@plindia.com | 91-22-66322391

Ahluwalia Contracts (India) (AHLU IN)

Rating: BUY | CMP: Rs237 | TP: Rs288

Higher provisions dent margins

Quick Pointers:

- Pick up in execution drives revenue growth (up 4.1% YoY) for the quarter while provisions for doubtful debts of ~Rs50mn dent margins.
- With healthy order inflows of Rs12.4bn till date, order book stands strong at Rs81.2bn (~4.4x trailing revenues).
- Labour availability stands at 80% pre-covid levels (vs 60% pre-covid levels by Sep'20); Company expects to reach ~100% by Dec'20.

Ahluwalia Contracts (ACIL) posted a strong quarterly performance with execution rising 4.1% YoY (vs PLe 23% decline) led by rise in labour availability. Labour availability stands 80% pre-covid levels (up from 60% in Sep'20). Margins were weak despite healthy execution and several cost control measures primarily due to provision of Rs50mn towards receivables and similar trend is expected to continue in 3Q and 4Q. Considering uncertainty regarding pandemic, management cited caution on execution. However, management indicated that working capital has improved as disbursements have started from state authorities primarily in West Bengal and Bihar and expects normalcy by Dec'20.

ACIL is among few EPC companies which have turned around with significant improvement in profitability through sound business strategy, focus on asset light business model, prudent selection of orders (state & central agencies) and better working capital management. Given strong 1H, we have revised our FY21 earnings estimate from Rs636mn to Rs783mn. At CMP, the stock trades at a P/E of 20.3x/ 8.6x on FY21E/ FY22E EPS and is trading at an EV of 9x/ 4.4x FY21E/ FY22E EBITDA. We maintain BUY rating on the stock with a TP of Rs288 (Same as earlier).

Healthy execution; margins fail to pick-up: For Q2FY21, ACIL's revenues grew 4.1% YoY to Rs4.3bn (PLe Rs3.2bn), led by robust execution of its strong order book and rising labour force. EBITDA declined by ~10.7% YoY to Rs342mn as EBITDAM softened 130bps YoY to 7.9% (PLe 8%) led by provisions of Rs50mn towards receivables. PBT was largely flat YoY at Rs241mn, while adj. PAT rose 42% YoY to Rs180mn (PLe Rs61mn), led by higher other income at Rs70mn (vs Rs20mn YoY) and lower effective tax rate at 24% (vs 47% YoY).

Robust order inflows lead to comfortable order book: The company bagged projects worth Rs12.4bn till date and is further L-1 in orders of Rs5bn from Sion hospital. Order book remains strong at Rs81.2bn (4.4x TTM revenues) on date providing comfortable revenue visibility for next two-three years. The order book comprises of Hospital segment (52%), Institutional (24%), Commercial (7%), Residential (12%) and Infrastructure segment (5%). Gross debt continues to remain low at ~Rs440mn with healthy cash & cash equivalents of ~Rs2.2bn as on 2QFY21. Working capital has improved significantly led by steady disbursement from State (Bihar & West Bengal) and Central Govt. authorities.

Y/e March (Rs mn)	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21	YoY gr. (%)	QoQ gr. (%)	1HFY21	1HFY20	YoY gr. (%)
Revenue	4,173	4,980	5,492	2,498	4,345	4.1	73.9	6,844	7,341	-6.8
Total Revenues	4,173	4,980	5,492	2,498	4,345	4.1	73.9	6,844	7,341	-6.8
Expenditure	3,790	4,544	5,262	2,313	4,003	5.6	73.1	6,316	6,566	-3.8
as % of sales	90.8	91.3	95.8	92.6	92.1			92.3	89.5	
Consumption of RM	3,085	3,720	4,215	1,768	3,246	5.2	83.5	3,308	2,935	12.7
as % of sales	73.9	74.7	76.7	70.8	74.7			48.3	40.0	
Employee Cost	388	370	423	264	353	-9.1	33.3	617	750	-17.8
as % of sales	9.3	7.4	7.7	10.6	8.1			9.0	10.2	
Other expenditure	317	454	625	280	405	27.8	44.4	2,391	2,882	-17.0
as % of sales	7.6	9.1	11.4	11.2	9.3			34.9	39.3	
EBITDA	383	436	230	185	342	-10.7	84.5	527	774	-31.9
Depreciation	79	81	81	72	73	-7.8	1.3	146	157	-7.0
EBIT	303	355	149	113	269	-11.4	137.7	382	618	-38.2
Other Income	20	25	29	71	70	254.0	-0.8	141	50	179.5
Interest	85	93	101	83	98	14.8	18.4	181	155	16.3
PBT	238	286	77	101	241	1.2	138.7	342	513	-33.4
Total Tax	112	75	16	26	61	-45.4	134.4	87	209	-58.3
Adjusted PAT	126	211	61	75	180	42.7	140.2	254	304	-16.4
(Profit)/loss from JV's/Ass/MI	0	0	0	0	0	0.0	0.0	0	0	0.0
PAT after MI	126	211	61	75	180	42.7	140.2	254	304	-16.4
Extra ordinary items	0	0	0	0	0	0.0	0.0	0	0	0.0
Reported PAT	126	211	61	75	180	42.7	140.2	254	304	-16.4
Adjusted EPS	2	3	1	1	3	42.7	140.2	4	5	-16.4
						bps	bps			bps
EBIDTA	9.2	8.7	4.2	7.4	7.9	-130	45	7.7	10.5	-285
EBIT	7.3	7.1	2.7	4.5	6.2	-109	166	5.6	8.4	-284
EBT	5.7	5.7	1.4	4.0	5.5	-16	150	5.0	7.0	-200
PAT	3.0	4.2	1.1	3.0	4.1	112	114	3.7	4.1	-43
Effective Tax rate	47.1	26.1	20.3	25.8	25.4	-2168	-46	25.5	40.7	-1519

Exhibit 1: Quarterly Financials	(Standalone): Modest margins despite strong pick-up in execution level	els
Exhibit In quarterry Finanoiale	(orandalono). modeor margino deopre or ong plot up in execution for	

Source: Company, PL

Exhibit 2: Key Assumptions

Y/e March (Rs mn)	FY18	FY19	FY20	FY21E	FY22E	FY23E
Order inflow	11,673	47,187	32,380	30,761	38,451	48,064
Revenues	16,466	17,547	18,849	17,915	27,299	31,023
Order book	30,740	60,380	74,620	87,466	98,619	1,15,659
Execution cycle (%)	35%	23%	20%	17%	22%	21%
Ob to sales (x)	1.9	3.4	4.0	4.9	3.6	3.7

Source: Company, PL

Concall Highlights

- Revenues for Q2FY21 grew by 4.1% YoY led by significant execution pickup across its project sites as labour availability increased.
 - Labour availability has risen to 80% pre covid levels vs 60% by Sep'20 end.
 - Management expects the labour availability to increase 100% pre covid level by Dec'20.
- Despite cost control initiatives & healthy execution, EBITDA margins came in at 7.9% vs 9.2% in 2QFY20 primarily due to provisions made of Rs50mn for receivables. Adjusting to this, EBIDTA margins stands at 9% for the quarter.
 - Going forward, management expects such provisions to continue as uncertainty regarding pandemic continues.
 - On account of write back of Labilities to the tune of Rs30mn, other income was higher at Rs70mn (up 254% YoY) during the quarter.
- The company secured projects worth ~Rs7.7bn taking its order book to Rs75.9bn (4.4x TTM revenues) as on 2QFY21. Order book comprises of Hospital segment (52%), Institutional Segment (24%), Commercial (7%), Residential (12%) and Infrastructure segment (5%) respectively.
 - The company has secured orders worth Rs12.4bn till date and is further L1 in order worth Rs5bn from Sion hospital project in Mumbai.
 - Despite healthy bid pipeline, management would be cautious on bidding and expects additional order inflows of Rs10bn for FY21E.
- In terms of working capital, management has seen significant improvement even in states such as Bihar and West Bengal as payments are being released.
- Gross debt stand continues to remain low at Rs440mn (same as 1Q) with healthy cash & cash equivalents of Rs2.2bn.
- Management continues to refrain from giving any guidance for FY21 considering the ongoing uncertainty due to Covid-19.
- The company incurred a capex of Rs87mn in 1HFY21 out of total plan outlay of Rs250-300mn.

Ahluwalia Contracts (India)

FY22E

FY23E

Financials

Income Statement (Rs m)

income Statement (RS m)					Dalance Sheet Abstract (KS		
Y/e Mar	FY20	FY21E	FY22E	FY23E	Y/e Mar	FY20	FY21E
Net Revenues	18,849	17,915	27,299	31,023	Non-Current Assets		
YoY gr. (%)	7.4	(5.0)	52.4	13.6			
Cost of Goods Sold	9,047	8,241	12,830	14,581	Gross Block	2,005	2,255
Gross Profit	9,803	9,674	14,468	16,442	Tangibles	2,005	2,255
Margin (%)	52.0	54.0	53.0	53.0	Intangibles	-	-
Employee Cost	1,543	2,150	2,184	2,482			
Other Expenses	1,693	1,254	1,911	2,172	Acc: Dep / Amortization	931	1,247
					Tangibles	931	1,247
EBITDA	1,530	1,612	3,139	3,568	Intangibles	-	-
YoY gr. (%)	(29.3)	5.4	94.7	13.6			
Margin (%)	8.1	9.0	11.5	11.5	Net fixed assets	1,074	1,009
					Tangibles	1,074	1,009
Depreciation and Amortization	319	316	417	485	Intangibles	-	-
EBIT	1,211	1,297	2,723	3,082	Capital Work In Progress	12	12
Margin (%)	6.4	7.2	10.0	9.9	Goodwill	-	-
					Non-Current Investments	1,502	1,547
Net Interest	350	419	428	460	Net Deferred tax assets	236	236
Other Income	104	166	154	142	Other Non-Current Assets	882	948
Profit Before Tax	966	1,044	2,449	2,765	Current Assets		
Margin (%)	5.1	5.8	9.0	8.9	Investments	-	-
					Inventories	2,208	2,454
Total Tax	322	261	612	691	Trade receivables	5,973	7,362
Effective tax rate (%)	33.3	25.0	25.0	25.0	Cash & Bank Balance	2,439	2,268
					Other Current Assets	3,152	3,319
Profit after tax	644	783	1,837	2,074	Total Assets	17,364	19,146
Minority interest	-	-	-	-			
Share Profit from Associate	-	-	-	-	Equity		
					Equity Share Capital	134	134
Adjusted PAT	644	783	1,837	2,074	Other Equity	7,906	8,674
YoY gr. (%)	(45.1)	21.5	134.6	12.9	Total Networth	8,040	8,807
Margin (%)	3.4	4.4	6.7	6.7			
Extra Ord. Income / (Exp)	-	-	-	-	Non-Current Liabilities		
					Long Term borrowings	446	446
Reported PAT	644	783	1,837	2,074	Provisions	-	-
YoY gr. (%)	(45.1)	21.5	134.6	12.9	Other non current liabilities	-	-
Margin (%)	3.4	4.4	6.7	6.7			
					Current Liabilities		
Other Comprehensive Income	-	-	-	-	ST Debt / Current of LT Debt	465	465
Total Comprehensive Income	644	783	1,837	2,074	Trade payables	5,231	5,399
Equity Shares O/s (m)	67	67	67	67	Other current liabilities	3,418	4,265
EPS (Rs)	9.6	11.7	27.4	31.0	Total Equity & Liabilities	17,364	19,146

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

iross Block	2,005	2,255	2,555	2,855
Tangibles	2,005	2,255	2,555	2,855
Intangibles	-	-	-	-
cc: Dep / Amortization	931	1,247	1,663	2,149
Tangibles	931	1,247	1,663	2,149
Intangibles	-	-	-	-
let fixed assets	1,074	1,009	892	707
Tangibles	1,074	1,009	892	707
Intangibles	-	-	-	-
capital Work In Progress	12	12	12	12
Goodwill	-	-	-	-
Ion-Current Investments	1,502	1,547	1,457	1,506
let Deferred tax assets	236	236	236	236
Other Non-Current Assets	882	948	1,128	1,331
current Assets				
Investments	-	-	-	-
Inventories	2,208	2,454	3,740	4,250
Trade receivables	5,973	7,362	8,227	9,350
Cash & Bank Balance	2,439	2,268	2,985	3,347
Other Current Assets	3,152	3,319	3,385	3,728
otal Assets	17,364	19,146	22,097	24,550
quity				
Equity Share Capital	134	134	134	134
Other Equity	7,906	8,674	10,474	12,506
otal Networth	8,040	8,807	10,608	12,640
Ion-Current Liabilities				
Long Term borrowings	446	446	446	446
Provisions	-	-	-	-
Other non current liabilities	-	-	-	-
urrent Liabilities				
ST Debt / Current of LT Debt	465	465	465	465
Trade payables	5,231	5,399	5,983	5,950
Other current liabilities	3,418	4,265	4,831	5,285
otal Equity & Liabilities	17,364	19,146	22,097	24,550

Source: Company Data, PL Research

P

Cash Flow (Rs m)

FY20	FY21E	FY22E	FY23E
966	1,044	2,449	2,765
319	316	417	485
350	419	428	460
104	166	154	142
-	-	-	-
1,635	1,778	3,294	3,710
(358)	(1,003)	(1,199)	(1,856)
(322)	(261)	(612)	(691)
955	514	1,482	1,163
(613)	(250)	(300)	(300)
-	-	-	-
-	-	-	-
(613)	(250)	(300)	(300)
-	-	-	-
300	-	-	-
(16)	(16)	(37)	(41)
(350)	(419)	(428)	(460)
(1)	-	-	-
(67)	(435)	(465)	(501)
275	(170)	717	361
605	264	1,182	863
	966 319 350 104 - 1,635 (358) (322) 955 (613) - (613) - (613) - 300 (16) (350) (1) (67) 275	966 1,044 319 316 350 419 104 166 - - 1,635 1,778 (358) (1,003) (322) (261) 955 514 (613) (250) - - (613) (250) - - (613) (250) - - (613) (250) - - (613) (250) - - (300) - (16) (16) (350) (419) (1) - (67) (435) 275 (170)	966 1,044 2,449 319 316 417 350 419 428 104 166 154 - - - 1,635 1,778 3,294 (358) (1,003) (1,199) (322) (261) (612) 955 514 1,482 (613) (250) (300) - - - (613) (250) (300) - - - (613) (250) (300) - - - (613) (250) (300) - - - 300 - - (350) (419) (428) (1) - - (67) (435) (465) 275 (170) 717

Y/e Mar	FY20	FY21E	FY22E	FY23E
Per Share(Rs)				
EPS	9.6	11.7	27.4	31.0
CEPS	14.4	16.4	33.6	38.2
BVPS	120.0	131.5	158.4	188.7
FCF	9.0	3.9	17.6	12.9
DPS	0.2	0.2	0.5	0.6
Return Ratio(%)				
RoCE	14.3	13.9	25.6	24.6
ROIC	13.4	13.8	26.8	25.2
RoE	8.4	9.3	18.9	17.8
Balance Sheet				
Net Debt : Equity (x)	(0.2)	(0.2)	(0.2)	(0.2)
Net Working Capital (Days)	56	77	66	77
Valuation(x)				
PER	24.6	20.3	8.6	7.7
P/B	2.0	1.8	1.5	1.3
P/CEPS	16.5	14.5	7.0	6.2
EV/EBITDA	9.4	9.0	4.4	3.8
EV/Sales	0.8	0.8	0.5	0.4
Dividend Yield (%)	0.1	0.1	0.2	0.3

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q3FY20	Q4FY20	Q1FY21	Q2FY21
Net Revenue	4,980	5,492	2,498	4,345
YoY gr. (%)	19.0	14.4	(21.1)	4.1
Raw Material Expenses	-	-	-	-
Gross Profit	4,980	5,492	2,498	4,345
Margin (%)	100.0	100.0	100.0	100.0
EBITDA	436	230	185	342
YoY gr. (%)	(12.2)	(59.5)	(52.7)	(10.7)
Margin (%)	8.7	4.2	7.4	7.9
Depreciation / Depletion	81	81	72	73
EBIT	355	149	113	269
Margin (%)	7.1	2.7	4.5	6.2
Net Interest	93	101	83	98
Other Income	25	29	71	70
Profit before Tax	286	77	101	243
Margin (%)	5.7	1.4	4.0	5.6
Total Tax	75	16	26	61
Effective tax rate (%)	26.1	20.3	25.8	25.1
Profit after Tax	211	61	75	182
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	211	61	75	180
YoY gr. (%)	(21.6)	(80.3)	(58.1)	42.7
Margin (%)	4.2	1.1	3.0	4.1
Extra Ord. Income / (Exp)	-	-	-	3
Reported PAT	211	61	75	182
YoY gr. (%)	(21.6)	(80.3)	(58.1)	44.7
Margin (%)	4.2	1.1	3.0	4.2
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	211	61	75	182
Avg. Shares O/s (m)	67	67	67	67
EPS (Rs)	3.2	0.9	1.1	2.7

Source: Company Data, PL Research

Ahluwalia Contracts (India)

Ahluwalia Contracts (India)



Recommendation History



No.	Date	Rating	TP (Rs.) Share P	rice (Rs.)
1	08-Oct-20	BUY	288	231
2	14-Aug-20	BUY	288	244
3	07-Jul-20	BUY	264	215
4	01-Jul-20	BUY	264	211
5	07-Apr-20	Accumulate	264	142
6	14-Feb-20	Accumulate	296	328
7	10-Jan-20	Accumulate	283	295
8	03-Jan-20	Accumulate	283	284
9	23-Dec-19	Accumulate	283	280

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	ABB	Hold	880	894
2	Ahluwalia Contracts (India)	BUY	288	231
3	Ashoka Buildcon	BUY	147	69
4	Bharat Electronics	Hold	99	94
5	BHEL	Hold	34	28
6	Capacite's Infraprojects	BUY	162	144
7	Container Corporation of India	BUY	468	378
8	Cummins India	Accumulate	472	434
9	Engineers India	BUY	104	64
10	GE T&D India	Hold	86	86
11	H.G. Infra Engineering	BUY	259	186
12	IRB Infrastructure Developers	BUY	152	109
13	ITD Cementation India	BUY	67	50
14	J.Kumar Infraprojects	BUY	176	105
15	Kalpataru Power Transmission	BUY	296	251
16	KEC International	Accumulate	339	338
17	KNR Constructions	BUY	336	255
18	Larsen & Toubro	BUY	1,284	935
19	NCC	BUY	83	36
20	PNC Infratech	BUY	219	167
21	Power Grid Corporation of India	BUY	205	170
22	Sadbhav Engineering	BUY	87	48
23	Siemens	BUY	1,402	1,275
24	Thermax	Accumulate	798	790
25	Triveni Turbine	BUY	85	69
26	Voltamp Transformers	BUY	1,283	1,032

PL's Recommendation Nomenclature (Absolute Performance)

Buy	:	> 15%
Accumulate	:	5% to 15%
Hold	:	+5% to -5%
Reduce	:	-5% to -15%
Sell	:	< -15%
Not Rated (NR)	:	No specific call on the stock
Under Review (UR)	:	Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/l, Mr. Viral Shah- BE Chemical Engineering, MBA Finance, Mr. Shivang Joshi- CA, MCom Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Viral Shah- BE Chemical Engineering, MBA Finance, Mr. Shivang Joshi- CA, MCom Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com